Literature DB >> 2270440

Distribution and characterization of autoantibodies to interleukin 1 alpha in normal human sera.

M Svenson1, M Bagge Hansen, K Bendtzen.   

Abstract

Antibodies against IL-1 alpha were detected in sera of apparently healthy individuals. The immunoglobulins belonged to the IgG class, particularly IgG1, IgG2, and IgG4. [125I]rIL-1 alpha bound to Fab fragments of IgG, and IgG immune complexes of molecular weights from 160 to 700 kDa were formed in the sera by [125I]rIL-1 alpha. The occurrence of detectable anti-IL-1 alpha IgG in sera of 32 male and 32 female donors was 25 and 22% respectively. As judged by Scatchard analysis of the binding data, the capacity and avidity of binding were greater in the male than in the female sera (mean capacity to bind [125I]rIL-1 alpha: 10 [0.7-27] versus 3.3 [0.5-7.3] ng/ml; and mean Kd: 5.5 [5-7] versus 11 [4-16] pM). The antibodies did not cross-bind human recombinant IL-1 beta, IL-2, IL-6, or tumour necrosis factor alpha (TNF-alpha). It is concluded that native IL-1 alpha seems to trigger production of specific, high-avidity IgG antibodies in a relatively large number of normal individuals. These autoantibodies may regulate immunoinflammatory processes involving IL-1 alpha.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2270440     DOI: 10.1111/j.1365-3083.1990.tb03212.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  11 in total

1.  Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations.

Authors:  M Wadhwa; A Meager; P Dilger; C Bird; C Dolman; R G Das; R Thorpe
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

2.  Anti-interleukin 1alpha autoantibodies.

Authors:  P Miossec
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

Review 3.  Facing the enigma of immunomodulatory effects of intravenous immunoglobulin.

Authors:  Tal Sapir; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

4.  Administration of intravenous immunoglobulin (IVIG) in vivo--down-regulatory effects on the IL-1 system.

Authors:  P Aukrust; F Müller; M Svenson; I Nordøy; K Bendtzen; S S Frøland
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

5.  Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.

Authors:  A Meager; M Wadhwa; C Bird; P Dilger; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

6.  Detection of autoantibodies to cytokines.

Authors:  K Bendtzen; M B Hansen; C Ross; M Svenson
Journal:  Mol Biotechnol       Date:  2000-03       Impact factor: 2.695

7.  Serum-induced suppression of interferon (IFN) activity. Lack of evidence for the presence of specific autoantibodies to IFN-alpha in normal human sera.

Authors:  M B Hansen; M Svenson; K Bendtzen
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

8.  Binding of cytokines to pharmaceutically prepared human immunoglobulin.

Authors:  M Svenson; M B Hansen; K Bendtzen
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

9.  Autoantibodies against interleukin 1alpha in rheumatoid arthritis: association with long term radiographic outcome.

Authors:  N A Graudal; M Svenson; U Tarp; P Garred; A-G Jurik; K Bendtzen
Journal:  Ann Rheum Dis       Date:  2002-07       Impact factor: 19.103

10.  High avidity IFN-neutralizing antibodies in pharmaceutically prepared human IgG.

Authors:  C Ross; M Svenson; M B Hansen; G L Vejlsgaard; K Bendtzen
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.